Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance

详细信息    查看全文

• 作者：Akbar Ali ; Cihan Aydin ; Reinhold Gildemeister ; Keith P. Romano ; Hong Cao ; Ay艧eg眉l 脰zen ; Djade Soumana ; Alicia Newton ; Christos J. Petropoulos ; Wei Huang ; Celia A. Schiffer
• 刊名：ACS Chemical Biology
• 出版年：2013
• 出版时间：July 19, 2013
• 年：2013
• 卷：8
• 期：7
• 页码：1469-1478
• 全文大小：590K
• 年卷期：v.8,no.7(July 19, 2013)
• ISSN：1554-8937

文摘

The hepatitis C virus (HCV) infects an estimated 150 million people worldwide and is the major cause of viral hepatitis, cirrhosis, and liver cancer. The available antiviral therapies, which include PEGylated interferon, ribavirin, and one of the HCV NS3/4A protease inhibitors telaprevir or boceprevir, are ineffective for some patients and cause severe side effects. More potent NS3/4A protease inhibitors are in clinical development, but the long-term effectiveness of these drugs is challenged by the development of drug resistance. Here, we investigated the role of macrocycles in the susceptibility of NS3/4A protease inhibitors to drug resistance in asunaprevir, danoprevir, vaniprevir, and MK-5172, with similar core structures but varied P2 moieties and macrocyclizations. Linear and macrocyclic analogues of these drugs were designed, synthesized, and tested against wild-type and drug-resistant variants R155K, V36M/R155K, A156T, and D168A in enzymatic and antiviral assays. Macrocyclic inhibitors were generally more potent, but the location of the macrocycle was critical for retaining activity against drug-resistant variants: the P1鈥揚3 macrocyclic inhibitors were less susceptible to drug resistance than the linear and P2鈥揚4 macrocyclic analogues. In addition, the heterocyclic moiety at P2 largely determined the inhibitor resistance profile, susceptibility to drug resistance, and the extent of modulation by the helicase domain. Our findings suggest that to design robust inhibitors that retain potency to drug-resistant NS3/4A protease variants, inhibitors should combine P1鈥揚3 macrocycles with flexible P2 moieties that optimally contact with the invariable catalytic triad of this enzyme.